mRNA Vaccines for Influenza: Hope for a Universal Vaccine?
Authors:
- 15 June 2026
- journal article
- Published by Springer Nature in BioDrugs
- Vol. 40 (4) , 581-597
Abstract
Seasonal influenza epidemics and pandemics remain a persistent public health threat. A universal influenza vaccine is urgently needed. Such a vaccine must accommodate rapid viral evolution, strain diversity-including types A and B and their many subtypes-and the complexities of human immune history and biases. Messenger RNA (mRNA)-formulated lipid-nanoparticles have evolved from an emergency pandemic vaccine experiment into a versatile vaccine platform. This technology has demonstrated potential to address several critical challenges in developing a universal influenza vaccine, including rapid strain updates, the production of high-valent formulations, and the ability to target conserved antigens that may induce broader and longer-lasting protection. This review summarizes recent studies and applications of multivalent antigen selection strategies and self-amplifying and circular RNA vaccine platforms to develop mRNA influenza vaccines to achieve vaccine universality, with an emphasis on immune responses against conserved targets. We also review the latest advances in generating long-term mucosal immunity against influenza through optimized mRNA delivery. Finally, we discuss practical considerations for correlates of protection, manufacturing, and accessibility, pioneering mRNA vaccine candidates heading to clinical trials, and milestones that define vaccine "universality."Keywords
Funding Information
- Division of Microbiology and Infectious Diseases (R01AI101047)
This publication has 165 references indexed in Scilit:
- Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 YearsJAMA, 2025
- Muco‐Penetrating Lipid Nanoparticles Having a Liquid Core for Enhanced Intranasal mRNA DeliveryAdvanced Science, 2025
- Viral Live‐Attenuated Vaccines (LAVs): Past and Future DirectionsAdvanced Science, 2024
- Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in micemLife, 2023
- Polymer‐Based mRNA Delivery Strategies for Advanced TherapiesAdvanced Healthcare Materials, 2023
- Oral and intranasal vaccines against SARS‐CoV‐2: Current progress, prospects, advantages, and challengesImmunity, Inflammation and Disease, 2022
- Rational design of anti‐inflammatory lipid nanoparticles for mRNA deliveryJournal of Biomedical Materials Research Part A, 2022
- Recent advances and current challenges in process intensification of cell culture‐based influenza virus vaccine manufacturingThe Canadian Journal of Chemical Engineering, 2021
- Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19JAMA, 2021
- A brief review of influenza virus infectionJournal of Medical Virology, 2021